BIRMINGHAM, Ala. (AP) — BioCryst Pharmaceuticals Inc. said Tuesday it entered marketing partnerships to help sell its experimental flu treatment peramivir in Mexico, Brazil, China, and Israel. BioCryst did not disclose terms of the partnerships, but said its partners will look for opportunities to distribute the vaccine to stockpiles, and to market peramivir as a seasonal flu treatment. The partners are moksha8 Pharmaceuticals for Brazil and Mexico, NT Pharma for China, and Neopharm Group in Israel. Peramivir is intended to be an intravenous treatment for the flu. BioCryst is preparing to run late stage tests in the U.S., although if there is a severe flu outbreak, the drug could be approved for emergency use. On Sunday, researchers testing the drug in Asia reported that a single dose of peramivir cleared up flu symptoms as well as five days of Tamiflu pills. In premarket trading, shares of BioCryst advanced 92 cents, or 8.6 percent, to $11.65. The stock has ranged from 85 cents to $13.47 over the past year.